About Us

The IQ MPS is a collaboration of pharmaceutical and biotechnologies companies created as an Affiliate within the International Consortium for Innovation and Quality in Pharmaceutical Development (also known as the IQ Consortium). The IQ Consortium is a leading science-focused, not-for-profit organization with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community (https://iqconsortium.org). The IQ MPS Affiliate was established to provide a venue for appropriate cross-pharma collaboration and data sharing to facilitate the industry implementation and qualification of MPS models. The IQ MPS Affiliate is a not-for-profit organization devoted to raising awareness, advancing the science, and supporting the implementation of microphysiological systems in drug discovery. As such, the IQ MPS Affiliate does not collectively endorse microphysiological systems developers or their products. Presentations to the IQ MPS Affiliate are for awareness and information purposes. Individual IQ MPS Affiliate member organizations may engage external organizations as they see fit.

MPS 3d Model.png


The Steering Committee provides strategic oversight of the initiative's portfolio and is the primary decision-making body for the IQ MPS Affiliate. The Steering Committee has representation from all member companies and acts on the recommendations of working groups and member companies to establish objectives, policies, and plans of action on a consensus basis.

The Executive Committee provides leadership and guidance in the management of the business and affairs of the consortium between meetings of the Steering Committee, implements strategic plans recommended by the Steering Committee, and provides general counsel and tactical advice in support of IQ MPS’s Working Groups.


Terry Van Vleet, PhD, DABT

Past Chair (2020-2021)

Director of Investigative Toxicology, AbbVie

Read More


Jason Ekert, PhD, MBA

Chair (2021-2022)

Senior Director, 


Read More


Szczepan Baran, MS VMD

Vice Chair (2021-2022)

Head of Emerging Technologies, Novartis

Read More


Rhiannon N. Hardwick, PHD, DABT

Vice Chair Elect (2021-2022)

Senior Scientist, Translational Safety Sciences, Theravance Biopharma

Read More

Working Groups

Publish manuscripts outlining organ-specific industry requirements for MPS platforms.

Organotypic Manuscripts

Identify opportunities to engage with health authorities globally on topics related to MPS qualification.


Initiate near-term proof of concept study (POC) study for data sharing or prospective collaboration for qualifying MPS system(s) based on specific COUs.

Pilot Project

Communicate industry perspective and build relationships with key MPS stakeholder to enhance the inclusion of industry priorities.

Communications and External Outreach

Gap Survey

Conduct and analyze a survey benchmarking how pharmaceutical companies are currently using microphysiological models.


AbbVie, Inc.
Alnylam Pharmaceuticals, Inc.
Amgen, Inc
Astellas Pharma US, Inc.
Boehringer Ingelheim
Bristol-Myers Squibb Company
Eisai, Inc.
Eli Lilly and Company
Genentech, Inc.


Janssen Pharmaceuticals, Inc.
Merck & Co., Inc.
Merck Healthcare KGaA
Novartis Pharmaceuticals Corporation
Theravance Biopharma
Vertex Pharmaceuticals Incorporated